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Abstract 
Background: Endometriosis is a common gynaecological disorder affecting 5–10% of women of reproductive 
age who often experience chronic pelvic pain and infertility. Definitive diagnosis is through laparoscopy, exposing 
patients to potentially serious complications, and is often delayed. Non-invasive biomarkers are urgently required to 
accelerate diagnosis and for triaging potential patients for surgery.
Methods: This retrospective case control biomarker discovery and validation study used quantitative 2D-difference 
gel electrophoresis and tandem mass tagging–liquid chromatography–tandem mass spectrometry for protein 
expression profiling of eutopic and ectopic endometrial tissue samples collected from 28 cases of endometriosis and 
18 control patients undergoing surgery for investigation of chronic pelvic pain without endometriosis or prophylactic 
surgery. Samples were further sub-grouped by menstrual cycle phase. Selected differentially expressed candidate 
markers (LUM, CPM, TNC, TPM2 and PAEP) were verified by ELISA in a set of 87 serum samples collected from the same 
and additional women. Previously reported biomarkers (CA125, sICAM1, FST, VEGF, MCP1, MIF and IL1R2) were also 
validated and diagnostic performance of markers and combinations established.
Results: Cycle phase and endometriosis-associated proteomic changes were identified in eutopic tissue from over 
1400 identified gene products, yielding potential biomarker candidates. Bioinformatics analysis revealed enrichment 
of adhesion/extracellular matrix proteins and progesterone signalling. The best single marker for discriminating endo-
metriosis from controls remained CA125 (AUC = 0.63), with the best cross-validated multimarker models improving 
the AUC to 0.71–0.81, depending upon menstrual cycle phase and control group.
Conclusions: We have identified menstrual cycle- and endometriosis-associated protein changes linked to various 
cellular processes that are potential biomarkers and that provide insight into the biology of endometriosis. Our data 
indicate that the markers tested, whilst not useful alone, have improved diagnostic accuracy when used in combina-
tion and demonstrate menstrual cycle specificity. Tissue heterogeneity and blood contamination is likely to have 
hindered biomarker discovery, whilst a small sample size precludes accurate determination of performance by cycle 
phase. Independent validation of these biomarker panels in a larger cohort is however warranted, and if successful, 
they may have clinical utility in triaging patients for surgery.
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Introduction
Endometriosis is estimated to affect 5–10% of women 
of reproductive age. Although some women with endo-
metriosis may be asymptomatic, it can cause signifi-
cant pain symptoms and infertility. The diagnosis of 
endometriosis can be difficult to achieve. Various stud-
ies worldwide have documented a delay of 7–11  years 
from appearance of symptoms until diagnosis [1–3]. 
This delay is partly due to the fact that an invasive lap-
aroscopy is needed to establish the diagnosis in some 
women. Imaging techniques are sensitive for diagnosis 
of ovarian endometriomas and deep endometriosis in 
experienced hands, but are less accurate for diagnosing 
other forms of endometriosis [4].
While efforts have been made to develop blood-
based diagnostic tests for endometriosis, few reported 
markers have been independently validated and none 
are in clinical use. As a result, definitive diagnosis of 
endometriosis remains surgical, requiring laparoscopy 
under general anaesthetic, exposing patients to poten-
tially serious complications. Difficulty in establishing a 
diagnosis leads to patients spending years on visits to 
their doctors and unnecessary investigations, adding 
to the significant economic burden of the disease [5]. 
While early stage endometriosis is not without conse-
quence, delay in diagnosis may allow disease progres-
sion with reduced treatment efficiency and poorer 
outcomes. There is clearly an urgent and unmet need 
for a minimally invasive diagnostic test for endometrio-
sis, though clinically useful blood-borne markers have 
yet to be found [6, 7]. The aim of a non-invasive test 
of endometriosis should be to expedite clinical diagno-
sis by achieving a high positive predictive value (> 90%) 
or to triage patients for laparoscopic investigation for 
conclusive pathological diagnosis. A lower sensitiv-
ity may be tolerated for the latter if specificity is high 
(> 90%). Ideally, a test would also need to function 
independently of menstrual cycle phase. Early diagno-
sis of endometriosis may allow preventative measures 
that delay progression of the disease such as use of the 
progesterone only pill or Mirena coil. Women hop-
ing to conceive or those who are refractory to medical 
management can be put forward for surgical treatment 
earlier.
The first aim of our study was to identify potential 
biomarkers through proteomic profiling of eutopic 
and ectopic endometrial tissue specimens taken from 
women with a confirmed diagnosis of endometriosis 
and relevant controls undergoing exploratory surgery 
for chronic pelvic pain without endometriosis or pro-
phylactic surgery due to strong familial risk of cancer. 
The second aim was to test these potential biomarkers 
in sera from a larger case control set of women, and 




Patients and samples were sourced from the Univer-
sity College London Hospital Gynaecology Depart-
ment following ethical approval and informed consent. 
Patients were those referred by their general practition-
ers or other clinicians for investigation of pelvic pain or 
for diagnosis and/or treatment of endometriosis. Those 
who agreed to undergo laparoscopic surgery for inves-
tigation and treatment of endometriosis, pelvic pain or 
bilateral salpingoophorectomy for strong family his-
tory of breast and ovarian cancer were approached and 
recruited. Inclusion criteria were as follows: ‘endome-
triosis cases’ were defined as women diagnosed with 
endometriosis at laparoscopy and confirmed histologi-
cally; ‘controls with pain’ were defined as symptomatic 
women with pelvic pain of unknown cause or chronic 
pelvic inflammatory disease without surgical evidence 
of endometriosis; ‘controls without pain’ were regularly 
cycling women with no known disease undergoing bilat-
eral tubal ligation and/or prophylactic bilateral salpin-
goophorectomy due to familial risk of breast and ovarian 
cancer and with no visual evidence of endometriosis at 
laparoscopy. The following women were excluded from 
the study; post-menopausal women, women with a posi-
tive pregnancy test or unknown pregnancy status on day 
of surgery, those with other benign conditions or malig-
nancies (particularly patients with fibroids and/or cancer 
were excluded as these conditions may compromise the 
integrity of the endometrium), women on any hormonal 
medication < 3 months prior to surgery and those whose 
surgical findings and pathological reports were inconsist-
ent. Cycle phase was determined by a triple approach to 
ensure accuracy; chronologically, by histological dating 
and by sex steroid hormone determination. Women with 
unconfirmed menstrual cycle stage were excluded. Addi-
tional patient data was collected including age, fertility 
history, treatment history (oral contraceptive and GnRH 
analogue use), menstrual cycle phase, pain history, histo-
pathology findings and anatomic characteristics of dis-
ease lesions. All patient records were handled per NHS 
confidentiality practices. Samples were anonymised and 
sequentially numbered. A lab coding system and data-
base were developed for recording anonymised patient 
and sample information.
Sample collection
Endometrial tissue biopsies (eutopic endometrium) were 
obtained by Pipelle cannula or curettage from women 
undergoing laparoscopy. Ectopic endometrial tissue 
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(endometriosis) samples were obtained from the same 
women at laparoscopy. Superficial lesions and deep infil-
trating endometriosis samples only were used in this 
study, the rationale being that imaging techniques are 
sensitive enough for diagnosis of ovarian endometrio-
mas, but are less accurate for diagnosing endometriosis 
elsewhere in the pelvis.
A portion of each tissue specimen was fixed in 10% 
buffered formalin for histological examination, whilst 
remaining tissue was washed in sterile phosphate buff-
ered saline to remove excess blood. Tissues were dried 
using lint-free paper, transferred into weighed Eppen-
dorf tubes and snap-frozen in liquid nitrogen. Samples 
were transported to the lab and stored at − 80 °C. Cycle 
stage for each patient was determined by endometrial 
dating by an experienced histopathologist without prior 
knowledge of sample group according to [8]. Endometri-
otic lesions were confirmed histologically. Samples were 
excluded where there was insufficient tissue (< 20 mg wet 
weight). 10  mL of blood was also collected from each 
patient before surgery by venepuncture into two vacu-
tainer gel tubes. 5 mL of blood was used for determina-
tion of oestradiol, progesterone, CA125 and CRP levels 
using standard assays. The remaining sample was allowed 
to clot at room temperature for 1 h, centrifuged at 3000g 
for 10  min at 4  °C, the serum collected, aliquoted and 
stored at − 80  °C. In total, 87 women met the inclusion 
criteria who had donated a serum sample; 45 with endo-
metriosis, 21 controls with pain and no evidence of endo-
metriosis and 21 controls with no pain and no disease 
(Table 1).
Protein extraction, quality assessment, immunodepletion 
and pooling
Each snap-frozen tissue sample was weighed and homog-
enised by grinding in liquid nitrogen into a fine powder. 
Ground tissue was lysed in 2D lysis buffer (8 M urea, 4% 
w/v CHAPS and 10 mM Tris–HCl pH 8.3) using a ratio 
of 5  μL of lysis buffer per 1  mg of tissue at room tem-
perature to extract protein. Samples were sonicated and 
centrifuged at 3000g for 10 min at 4  °C to pellet insolu-
ble material. The supernatant was collected and protein 
concentration determined using a Bradford microtitre 
plate assay (Pierce) using a bovine serum albumin stand-
ard curve. All samples were normalised to the same 
(lowest) protein concentration using 2D lysis buffer. To 
assess quality of the samples, 10  μg total protein from 
each sample were run on  NuPAGE®  Novex® 4–12% 
Bis–Tris 1.5  mm, pre-cast SDS-PAGE gels (Invitrogen) 
alongside 10 μg of total protein from human serum. Gels 
were stained with colloidal Coomassie Blue (Instant 
Blue gel stain; Expedion) and imaged on a GS-800 den-
sitometer (BioRad). Samples were excluded if they com-
prised largely of serum proteins (i.e. barely visible tissue 
protein bands) and/or had low protein staining above 
20  kDa. Equal protein amounts from each sample were 
then pooled into 6 groups according to tissue type, case 
control status and menstrual cycle phase. These groups 
were: eutopic tissue from endometriosis cases in the 
secretory (ES; n = 19) or proliferative phase (EP; n = 9), 
eutopic tissue from patients with chronic pelvic pain with 
no evidence of endometriosis at laparoscopy in the secre-
tory phase (PS; n = 7), eutopic tissue from asymptomatic 
controls scheduled for risk-reducing surgery with no 
evidence of disease at laparoscopy in the secretory (CS; 
n = 6) or proliferative phase (CP; n = 7) and ectopic tissue 
from endometriosis cases in the secretory phase (EcS; 
n = 11). There were no eutopic samples available for the 
pain group in proliferative phase or eligible ectopic sam-
ples from endometriosis patients in proliferative phase. 
To improve proteomic coverage, immunodepletion of the 
12 most abundant serum proteins was carried out on the 
pooled samples using Protein Purify 12 (PP12) Human 
Serum Protein Immunodepletion resin (R&D). Briefly, 
500  μL of PP12 immunodepletion slurry was incubated 
with diluted endometrial tissue lysate (500 μg protein) on 
a rotary shaker for 30 min. Unbound material was recov-
ered using Spin-X Filter units by centrifugation, the fil-
trates were concentrated to 25 μL using 5 kDa molecular 
weight cut-off Vivaspin columns and protein concentra-
tion determined using the Bradford method.
2D‑DIGE profiling of endometrial tissue lysates
Immunodepleted samples (80  μg total protein) were 
labelled differentially in triplicate with NHS-cyanine dyes 
(GE Healthcare) at a dye to protein ratio of 6  pmol/μg 
protein on ice for 30 min in the dark. Cy2 dye was used 
to label an internal standard pool prepared by mixing 
equal amounts of protein from all pools. Reactions were 
Table 1 Characteristics of  subjects included in  the  study 
and clinical grouping
Control Pain Endometriosis
Number 21 21 45
Age (years)
 Mean (SD) 37.5 (8.5) 32.2 (6.5) 35.9 (5.8)
 Median (range) 36 (20–51) 33 (19–48) 36.0 (20–52)
Symptoms
 Subfertility 4 8 16
 Pain 0 22 38
Cycle phase
 Proliferative (1) 10 9 13
 Secretory (2) 9 12 26
 Inactive (0) 2 0 6
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quenched by adding a 20-fold molar excess of l-lysine to 
dye and incubating on ice for 10  min in the dark. Pairs 
of differentially labelled samples (Cy3 and Cy5) and Cy2-
labelled standard were mixed appropriately and reduced 
by addition of dithiothreitol (DTT) (65 mM final concen-
tration) and carrier ampholines and pharmalytes added 
to a final concentration of 2% v/v with 1 μL of 2% bromo-
phenol blue. Samples were then run on 9 2D-gels accord-
ing to our standard procedures [9]. Briefly, Immobiline 
IPG strips (24  cm; pH 3–10 NL) (GE Healthcare) were 
rehydrated with labelled samples overnight and isoelec-
tric focusing performed for 80 kVh at 16 °C. Strips were 
equilibrated with DTT reduction and iodoacetamide 
(IAM) alkylation steps, transferred onto 10% SDS-PAGE 
bonded gels cast between low fluorescence glass plates, 
overlaid with agarose and run for 16 h at 2.2 W per gel. 
Images were acquired by scanning gels on a Typhoon 
9400 multi-wavelength fluorescence imager (GE Health-
care) and analysed using DeCyder Software V6 (GE 
Healthcare), calculating standardised spot abundances 
(using the Cy2-labelled standard pool) for all matched 
spots across the 9 gel images. Differences in spot abun-
dances between conditions were filtered by specifying a 
1.5 threshold of average fold-change with P < 0.05 (Stu-
dent’s t test). Pick lists of spots of interest were created 
and exported to an Ettan spot picking robot (GE Health-
care) for excision from the same colloidal Coomassie 
Blue post-stained gels.
Protein identification by LC–MS/MS
In-gel digestion was carried out by washing gel pieces 
three times in 200  µL of 50% acetonitrile (ACN) and 
then in 200 µL of 100% ACN. Gel pieces were dried in a 
SpeedVac for 20 min, reduced for 45 min with 20 µL of 
10 mM DTT in 5 mM ammonium bicarbonate (AmBiC) 
pH 8.0 at 50  °C, alkylated with 20  µL of 50  mM IAM 
in 5  mM AmBiC, washed twice in 200  µL of 50% ACN 
and dried in a SpeedVac. Gel pieces were then overlaid 
with 50 ng modified trypsin (Promega) in 10 µL of 5 mM 
AmBiC and incubated for 16 h at 37 °C. The supernatant 
was collected and peptides extracted twice with 20 µL of 
5% trifluoroacetic acid in 50% ACN and the supernatants 
pooled. Peptide extracts were vacuum dried, desalted 
using reversed phase C18 ZipTips™ (Merck Millipore) 
as per the manufacturer’s instructions, dried down in 
a SpeedVac and stored at − 20  °C prior to MS analysis. 
Digested samples were re-suspended in 6 μL of 0.1% (v/v) 
formic acid (FA) and analysed by LC–MS/MS using an 
Ultimate 3000 nano-flow reversed phase-liquid chro-
matography (RPLC) system linked to an LTQ-Orbitrap 
XL mass spectrometer (Thermo-Scientific) equipped 
with a Picoview PV550 nano-electrospray ion source 
(New Objective Inc.). Samples were first injected onto 
an Acclaim PepMap 100 C18 pre-column (5 μm, 100 Å, 
300  μm i.d × 5  mm) (Thermo Fisher) and washed for 
3 min with 90% buffer A  (H2O + 0.1% (v/v) FA) at a flow 
rate of 25 μL/min. Chromatographic separation was then 
performed on an Acclaim PepMap 100 C18 nano-LC col-
umn (3 μm, 100 Å, 75 μm i.d × 25 cm) (Thermo Fisher) 
with a 60 min linear gradient of 10–50% buffer B (100% 
ACN + 0.1% (v/v) FA) at a flow rate of 300 nL/min. Tan-
dem MS was performed in the data-dependent mode to 
automatically switch between MS (full ion scan) and MS/
MS (fragment ion scan) acquisition. Survey full scan MS 
spectra (m/z 390–1700) were acquired in the orbitrap 
with a resolution of 60,000 at m/z 400. The most intense 
(top 6 ions per survey scan) were sequentially isolated for 
fragmentation in the linear ion-trap by collision induced 
dissociation and dynamically excluded for 60 s. Acquired 
mass spectra were processed using Mascot Distiller ver-
sion 2.5 (Matrix Science Ltd) and searched against the 
SwissProt database. The following parameters and search 
filters were used; MS tolerance was 10 ppm, MS/MS tol-
erance was 0.5  Da, two missed cleavages were allowed, 
carbamidomethylation of cysteines was set as a fixed 
modification, methionine oxidation, acetylation (protein 
N-term) and deamidation (asparagine and glutamine) 
were set as variable modifications. Protein identifications 
were accepted where there were two unique peptides of 
score > 20 at a Mascot significant threshold of P < 0.05. 
Protein identifications were matched to specific spots in 
DeCyder with experimental molecular weights checked 
against theoretical values.
Profiling of endometrial tissues using a TMT‑based 3D–LC–
MS/MS strategy
A 6-plex tandem mass tagging (TMT) approach with 
3-dimensional peptide separation [strong anion exchange 
(SAX) chromatography, off-line high pH RPLC and low 
pH nano-RPLC coupled to MS/MS] was applied to the 6 
tissue lysate pools described above to maximise quanti-
tative proteomic coverage. Immunodepleted tissue lysate 
pools (100  μg each) were re-suspended in 100  mM tri-
ethylammonium bicarbonate (TEAB), pH 8.5 and 0.1% 
SDS, reduced with 1 mM tris(2-carboxyethyl)phosphine 
for 1 h at 55 °C and alkylated with 7.5 mM IAM for 1 h 
at RT in the dark. Samples were digested overnight at 
37  °C using 4  µg of modified porcine trypsin. Samples 
were then labelled with TMT reagents (Thermo Fisher). 
Briefly, each digested pool was labelled with 0.8  mg of 
one of six TMT reagents (re-suspended in 41 μL of ACN) 
for 1  h at RT as follows: CS—TMT126, CP—TMT127, 
PS—TMT128, EcS—TMT129, ES—TMT130 and EP—
TMT131. Samples were then incubated with 0.25% 
hydroxylamine for 30 min at RT to quench the reaction. 
The six TMT-labelled samples were then combined. SDS 
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was removed using detergent removal spin columns 
(Pierce) as per the manufacturer’s instructions, the sam-
ples desalted using 1 cc Oasis HLB cartridges (Waters) as 
per the manufacturer’s instructions, dried in a SpeedVac 
and re-suspended in 300 μL of 100 mM TEAB pH 8.5.
For SAX chromatography, DEAE ceramic HyperD F 
slurry (300 μL; Pall Corporation) was added to a spin fil-
ter unit and centrifuged at 3000 rpm for 2 min to remove 
storage buffer, then washed with 200 μL of 1 M NaCl in 
100 mM TEAB pH 8.5, then three times with 200 µL of 
200  mM TEAB pH 8.5 and then equilibrated by wash-
ing with 100 mM TEAB pH 8.5, followed by centrifuga-
tion at 3000  rpm for 2  min to remove the supernatant. 
The pooled sample was then incubated with the resin 
on a rotary shaker for 5  min. Un-bound peptides were 
removed by centrifugation followed by washing with 
200 µL of 100 mM TEAB and the two fractions combined 
as the flow-through. Bound peptides were then sequen-
tially eluted using 200 μL × 2 of increasing salt concentra-
tion buffer; 100 mM TEAB plus 400 mM NaCl, 600 mM 
NaCl and 1  M NaCl. The two eluates at each salt con-
centration were combined and desalted using 1 cc Oasis 
HLB cartridges, vacuum dried and stored at − 20 °C. For 
high pH RP-LC, peptide fractions were re-suspended in 
45  μL of 20  mM ammonium formate pH 8.5 and frac-
tionated on a Poroshell 300SB-C18 (5 μm, 2.1 × 75 mm) 
column using an Agilent 1100 series microflow pump. 
Briefly, 40 µL of re-suspended peptides were injected 
onto the column in 20 mM ammonium formate pH 8.5 
and peptides fractionated using a 0–45% linear gradient 
of 20 mM ammonium formate pH 8.5 in 80% acetonitrile 
at a flow rate of 200 µL/min for 55 min. 30 fractions were 
collected for each of the 4 SAX fractions (total 120 frac-
tions). Each fraction was dried, re-suspended in 200 μL of 
0.1% FA and re-dried prior to MS analysis.
LC–MS/MS was carried out essentially as described 
above, using a 90  min linear gradient of 10–50% buffer 
B, with data-dependent acquisition of the top 3 ions for 
fragmentation by both CID and HCD (collision energy 
40%) for optimal reporter ion measurement. For HCD, 
product ions were detected in the orbitrap at a resolu-
tion of 7500. Proteome Discoverer version 2.4 was used 
for protein identification and quantification using Mascot 
for searching the SwissProt database. Search parameters 
were as described above, except that only one missed 
cleavage was allowed. A co-isolation threshold of 25% 
was set in the quantification method to limit the record-
ing of reporter ion ratios from multiple peptides. Protein 
groups with a ratio above 1.5 or below 0.67 for each com-
parison were considered to be differentially expressed.
Gene ontology and pathway enrichment analysis
Differentially expressed proteins were imported into 
WebGestalt [10] and each clinical group analysed sepa-
rately for enrichment of GO biological process, molecu-
lar function and cellular component, GO Slim terms, 
protein interaction networks, KEGG pathways and 
disease association. Significantly enriched terms were 
identified using a hypergeometric test with a Benjamini–
Hochberg (BH) correction at a significance of P < 0.05. 
The top 10 GO terms with the most significant P values 
were reported. In each comparison, the protein lists were 
analysed separately as up- or down-regulated proteins.
Selection and verification of candidate biomarkers
For selection of proteins for verification, a biomarker 
scoring system was devised based on fold-change, TMT 
reporter ion ratio count, variability, number of unique 
peptide sequences, whether they were possible serum 
contaminants and their membership in 1 of 5 expres-
sion clusters. Clustering was performed using Graphical 
Proteomics Data Explorer (GProX) based on reporter ion 
ratios for the different comparisons with a higher score 
given to candidates whose expressions differed between 
endometriosis and both control groups and in both 
cycle phases. Selection was also weighted based on prior 
knowledge of function, proteins known to be secreted 
and those for which commercial detection reagents 
were available. LUM, TPM2, CPM, PAEP and TNC were 
selected from the discovery profiling work.
Promising candidate markers reported in the literature 
(sICAM1, MCP1, MIF, IL1R2, VEGF and FST) were also 
tested using commercial ELISA kits. Assays were tested 
for reproducibility and technical sensitivity to ensure the 
protein of interest could be accurately detected in serum 
samples. Optimal dilutions and intra-assay CVs for the 
assays are shown in Additional file  1: Table  S1. Assays 
were carried out according to the manufacturers’ instruc-
tions using the complete study set.
Statistical analysis
Data analysis was carried using Graphpad Prism software 
version 5.0.1 and the R statistical software environment. 
For samples where the protein of interest was determined 
to be below the limit of detection of the assay, the value 
of the lowest standard for that assay was used. The Sha-
piro–Wilk test was applied to test data distribution with 
an unpaired t test used to compare groups for normally 
distributed data and the Mann–Whitney test used for 
non-normally distributed data. For each clinical group, 
the data was analysed independently of cycle phase and 
then by cycle phase to assess menstrual cycle depend-
ency. A P value of < 0.05 was considered significant. To 
determine the diagnostic performance of each biomarker, 
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ROC curve analysis was performed with the area under 
the curve (AUC) reported for each comparison [endome-
triosis (E) vs. no-pain control (C) and endometriosis vs. 
pain control (P)]. Multi-variate analysis was carried out 
to assess the diagnostic performance of combined marker 
panels using logistic regression, reporting cross-validated 
(leave-one-out) AUC and sensitivity at fixed specificity.
Results
Discovery proteomic profiling by 2D‑DIGE
In total, 122 pre-menopausal women were consented to 
the study with 87 women meeting the inclusion criteria. 
The set was divided into cases who were diagnosed with 
endometriosis (n = 45) and two control groups compris-
ing women with pelvic pain (n = 21) or no known disease 
and no pain (n = 21). Eutopic and ectopic endometrial 
tissue specimens from these women were lysed and first 
quality-assessed by SDS-PAGE with colloidal Coomas-
sie Blue staining. It was evident that some samples were 
heavily contaminated with blood proteins, impairing the 
ability to visualise tissue-derived proteins at that protein 
load, or had low protein staining overall (see Additional 
file 1: Figure S1). These tissue samples were subsequently 
excluded from further analysis. The remaining samples 
were pooled (based on equal protein amount) into six 
groups by clinical group and cycle phase with 6–20 tis-
sue samples pooled per group (designated as CS, CP, PS, 
ES and EcS—see “Materials and methods” section). With 
blood protein contamination in mind, immunodepletion 
of the 12 most abundant serum proteins was undertaken 
to improve tissue protein coverage (Additional file 1: Fig-
ure S1). Contamination was significant, as immunode-
pletion resulted in protein yields of 20–25% of starting 
material, although the approach did reveal lower abun-
dance (tissue-derived) proteins.
2D-DIGE profiling was undertaken, analysing the 6 
pools in triplicate for differential protein expression. 
Merged fluorescent gel images are shown in Additional 
file  1: Figure S2. Differential expression was assessed 
using Decyder image analysis software, where spot 
matching was performed and standardised spot abun-
dances calculated with reference to a Cy2-labelled stand-
ard pool (equal mix of all samples) run on all gels. Spot 
abundances were compared between clinical groups 
revealing 72 protein spots matching on all 9 gel images 
that displayed a > 1.5-fold change in standardised abun-
dance (P < 0.05) between one or more clinical groups. 
Of these, 52 were detectable as well-defined colloidal 
Coomassie Blue-stained spots. These spots were excised, 
digested with trypsin and analysed by LC–MS/MS, 
resulting in 130 confident protein identifications (see 
Additional file 1: Table S2).
Since multiple proteins were identified in many of the 
spots, it was not possible to assign which protein was 
differentially expressed with absolute certainty. There-
fore, the most likely protein was assigned based on the 
number of matched peptides and concordance of theo-
retical and experimental molecular weights. Differen-
tially expressed proteins comprised cytoskeletal proteins, 
metabolic enzymes, extracellular matrix proteins, muscle 
proteins, those involved in protein folding and blood pro-
teins, including haemoglobin. A simple biomarker score 
was used to prioritise candidates for further testing and 
was based on proteins displaying the same directional-
ity of differential expression between endometriosis and 
both control groups and in ectopic versus eutopic tis-
sue and that did not differ between control groups (PS/
CS). High-scoring proteins included lumican (LUM) 
and tropomyosin β chain (TPM2). Expression of LUM 
(identified in 3 spots) was higher in the secretory phase 
endometriosis group compared to both control groups 
(e.g. spot 708; ES/CS = 1.86, P = 0.005; ES/PS = 2.25, 
P = 0.004) and in ectopic compared to eutopic tissue 
(EcS/ES = 2.09, P = 0.008), but not in proliferative phase 
samples (Additional file 1: Table S2). Similarly, expression 
of two proteoforms of TPM2 was higher in ectopic versus 
eutopic tissue and in secretory phase endometriosis com-
pared to control groups [e.g. spot 1548 (EcS/ES = 4.15, 
P = 0.0002; ES/CS = 3.15, P < 0.0001; ES/PS = 2.36, 
P = 0.0057)]. These differences suggest menstrual cycle 
dependency. LUM and TPM2 were selected for further 
testing as serum biomarkers.
Discovery proteomic profiling by 3D–LC–MS/MS with TMT 
labelling
To improve depth of coverage for candidate biomarker 
discovery, immunodepleted tissue pools were subjected 
to tryptic digestion, 6-plex TMT labelling and extensive 
peptide fractionation (120 fractions) using SAX, high 
pH RPLC and low pH nano RPLC linked on-line to tan-
dem MS. Results are presented in Additional file  2. A 
total of 1581 proteins groups were identified of which 
1433 (91%) had quantitative information across all 
clinical groups. To gain insight into the possible func-
tional consequences of altered protein expression, a 
functional enrichment analysis was undertaken using 
GO biological process and KEGG pathway terms for 
the differentially expressed proteins (> 1.5-fold). The 
results were somewhat ambiguous. Analysis of pro-
teins up-regulated in eutopic tissue from endometriosis 
patients, revealed enrichment of macromolecular com-
plex subunit organization, mRNA metabolic process, 
protein complex disassembly, translational termination, 
aromatic/cyclic compound metabolic process, nitrogen 
compound metabolic process, catabolic process and 
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Table 2 GO enrichment analysis for differentially regulated (≥ 1.5 fold-change) proteins
ES versus CS EP versus CP ES versus PS EcS versus ES






































































7.26E−11 4.41E−07 1.40E−05 2.75E−20
 Ribosome 4.72E−15 3.29E−16
 Focal adhe-
sion
2.21E−05 3.74E−05 1.48E−18 6.72E−32
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acute inflammatory response, with only enrichment 
of mRNA metabolic process shared for all three com-
parisons (Table  2). Down-regulated proteins were also 
enriched for macromolecular complex subunit organi-
zation, mRNA metabolic process, protein complex dis-
assembly and acute inflammatory response, with no 
enrichment common to the three comparisons. Com-
paring ectopic and eutopic tissue, nitrogen compound 
metabolic process, response to wound healing and 
cytoskeleton organisation were enriched for up-reg-
ulated proteins, whilst mRNA metabolic process and 
catabolic process were enriched for down-regulated 
proteins. KEGG pathway mapping revealed enrichment 
of genes involved in metabolic pathways, ribosome, 
proteasome, spliceosome and notably, regulation of 
the actin cytoskeleton, focal adhesions and extracellu-
lar matrix (ECM)-receptor interactions, although there 
was no obvious pattern to the enrichment across the 
comparisons (Table 2). Disease association enrichment 
was also ambiguous, although there was a trend of 
down-regulated gene products linked with carcinoma 
and neoplasm invasiveness. This is perhaps not surpris-
ing since endometriosis shares some features with can-
cer, such as local and distant invasion, attachment and 
damage to affected tissues. Numerous muscle-related 
proteins were identified that were highly expressed 
in ectopic versus eutopic tissue, including TPM1, 2, 3 
and 4, MYLK, MYL6 and 9, PDLIM7, CNN1, CALD1 
and TAGLN, suggestive of significant amounts of mus-
cle tissue in the ectopic samples (Additional file 2 and 
Table 3). ECM proteins including FN1, LUM, COL1A2, 
COL6A1, COL6A3, COL14A1, PRELP, OGN, DCN, 
BGN, FMOD and MFAP4, were also highly expressed 
in ectopic tissue.
Protein groups were scored for biomarker potential 
with carboxypeptidase M (CPM) the highest scoring, 
displaying increased endometrial expression in endo-
metriosis versus both control groups and in both cycle 
Table 2 (continued)
ES versus CS EP versus CP ES versus PS EcS versus ES









 Spliceosome 9.27E−06 9.31E−09 0.0005
































Enrichment analysis was performed using WebGestalt. Each clinical group was analysed separately for enrichment of biological process, KEGG pathways and disease 
association. Significantly enriched terms were identified using a hypergeometric test with a Benjamini-Hochberg (BH) correction with corrected P values shown for 
each comparison
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phases (ES/CS = 1.62, ES/PS = 2.53, EP/CP = 2.45) 
(Table 3). Its expression was however lower in ectopic 
tissue (EcS/ES = 0.32). Similarly, progesterone receptor 
(PGR) was over-expressed in endometriosis eutopic tis-
sue (ES/CS = 1.45, ES/PS = 1.76, EP/CP = 2.42), whilst 
decreased in ectopic tissue (EcS/ES = 0.32). Mem-
brane-associated progesterone receptor component 1 
(PGRMC1) was similarly over-expressed in prolifera-
tive endometriosis eutopic tissue versus control (EP/
CP = 1.56), and under-expressed in ectopic tissue (EcS/
ES = 0.61). The progesterone-regulated gene glycode-
lin (PAEP) was also under-expressed in ectopic tissue 
(EcS/ES = 0.21). Other proteins of interest were tenas-
cin C (TNC), up-regulated in endometriosis compared 
to both control groups (ES/CS = 1.82, ES/PS = 1.68, 
EP/CP = 1.50), and transgelin (TAGLN), increased in 
proliferative phase endometriosis versus controls (EP/
CP = 2.17) and ectopic versus eutopic tissue (EcS/
ES = 18.83). Notably, LUM and TPM2 were also identi-
fied with increased expression in ectopic tissue, simi-
lar to that observed by 2D-DIGE profiling, although 
were not altered appreciably in the eutopic tissue 
comparisons.
Testing candidates as serum biomarkers of endometriosis
From the tissue profiling, TNC, CPM, TPM2, LUM and 
PAEP were selected for further testing as serological 
markers using samples from 87 women (control n = 21; 
pain control n = 21; endometriosis n = 45) (Table 1). Bio-
marker candidates reported in the literature (sICAM1, 
MCP1, MIF, IL1R2, VEGF and FST) were also tested with 
CA125, progesterone, oestradiol and CRP. Commercial 
assays were first assessed using a test pool of all samples 
to determine optimal sample dilutions and reproducibil-
ity (Additional file 1: Table S1) and then run on the full 
set. Serum measurements were correlated with clinical 
group and cycle phase. Only CA125 and sICAM1 were 
significantly elevated (P < 0.05) when comparing endo-
metriosis to both control groups considering all cycle 
phases (Table  4A). Areas under the ROC curve for the 
endometriosis versus pain groups were 0.713 for CA125 
and 0.722 for sICAM1. TNC was significantly elevated 
in the pain group versus the control and endometriosis 
groups. In the secretory phase, CA125 elevation main-
tained significance when comparing endometriosis to 
both control groups, whereas sICAM1 was significantly 
raised only when comparing endometriosis and pain con-
trols (Table  4B). Elevation of VEGF became significant 
between endometriosis and non-pain controls in secre-
tory phase, whilst FST (lower in endometriosis) was the 
only candidate found to be significant when comparing 
groups in the proliferative phase. Together, these data 
suggest cycle dependency in the serum levels of some of 
the candidate markers.
Multi-marker logistic regression models were gen-
erated to assess if candidates would complement one 
another to improve classification. Generally, cross-val-
idated models for discriminating the endometriosis and 
pain groups (all phases) performed similarly to those 
discriminating the endometriosis and non-pain groups 
with sensitivities of 62–67% at 80% specificity (Table 5). 
sICAM1 featured in the best models for both groups, 
whilst CA125 was only included in models for discrimi-
nating endometriosis from the non-pain group. The best 
performing model [sICAM1, FST, TNC] for discriminat-
ing endometriosis from pain controls (E vs. P; all phases), 
gave a sensitivity of 67% at 80% specificity. When con-
sidering menstrual phase, for which both control groups 
were pooled, the best model [ICAM1, FST, oestradiol] 
gave 77% sensitivity at 80% specificity for detecting endo-
metriosis in the proliferative phase, whilst the best model 
for secretory phase samples [CA125, MIF, PAEP], gave a 
sensitivity of 65% at 80% specificity. This again highlights 
cycle-dependency in the performance of the biomarker 
panels.
Discussion
The aim of this study was a tissue-based discovery of 
potential new biomarkers of endometriosis with trans-
lation to serum-based tests aimed at non-invasive diag-
nosis. Promising biomarkers reported in the literature 
were also assessed. The main challenges experienced in 
the discovery was the heterogeneity of tissue samples and 
variable blood contamination. This was evidenced by the 
presence of variable levels of abundant fibro-muscular 
and serum proteins across the sample set that will have 
compromised the quality of the analysis. Whilst pooling 
would average out some of this heterogeneity, it is pos-
sible that outlier samples may skew the data leading to a 
higher false discovery rate. Despite this, a number of dif-
ferentially expressed proteins were identified as poten-
tial biomarkers that were assayed in serum samples and 
which contributed to multivariate models that could 
discriminate endometriosis from either or both control 
groups with reasonable accuracy.
Notably, we did not find CA125 or any of the previ-
ously reported candidate biomarkers using the prot-
eomic approaches described. CA125 exists at relatively 
low abundance and is an extremely large (up to 4 MDa), 
heterogeneously glycosylated protein. These proper-
ties would make sampling of CA125 using these meth-
ods unlikely—the protein is not likely to resolve well on 
2D gels due to its large size and heterogeneity, whilst its 
heavy modification may hinder efficient tryptic diges-
tion and decrease mass matching in database searches. 
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Similarly, we postulate that the other candidates 
(sICAM1, MCP1, MIF, IL1R2, VEGF and FST) exist at 
relatively low abundance in tissue, reducing the chance 
of their identification. This highlights that coverage of 
the proteome is still somewhat limited despite the multi-
dimensional approach used in our methodology.
Tissue profiling identified numerous differentially 
expressed proteins implicated in the implantation of 
endometriotic tissue beyond the endometrium and/or 
involved in disease progression. Although the enrichment 
analysis was somewhat ambiguous, multiple proteins 
involved in cytoskeletal and ECM organisation and cell–
matrix interactions were enriched. This supports findings 
from previous studies [11–14]. Adhesion to the perito-
neal ECM and invasion of retrograde-shed endometrial 
cells is one of the vital stages in implantation of ectopic 
endometrial cells and it is tempting to speculate that the 
adhesion/ECM proteins identified herein play important 
Table 4 (A) Median concentrations and ranges of individual biomarker candidates in serum and P values for comparison 
of  clinical groups in  all stages of  the  menstrual cycle. (B) Analysis by  menstrual cycle phase showing significant 
differences in candidate biomarker levels. P values < 0.05 are considered significant
C = no pain control; P = pain control; E = endometriosis; ns = not significant




CA125 U/mL 7.7 (1.3–28.0) 7.7 (0.6–273.0) 22.5 (0.70–386.6) 0.0007 0.0058 ns
oestradiol pmol/L 245 (18–2512) 419 (79–1616) 345 (18–2110) ns ns ns
progesterone nmol/L 1.9 (0.6–43.7) 6.1 (0.9–53.4) 2.3 (0.2–61.7) ns ns ns
sICAM1 ng/mL 301.4 (81.9–502.3) 265.7 (85.83–624.7) 342.1 (92.3–730.8) 0.04 0.004 ns
IL1R2 ng/mL 12.72 (7.65–19.23) 11.33 (6.41–23.29) 12.35 (0.57–23.2) ns ns ns
MCP1 ng/mL 0.32 (0.10–1.55) 0.26 (0.07–1.39) 0.27 (0.03–2.25) ns ns ns
MIF ng/mL 24.81 (2.20–106.3) 30.87 (2.22–282.8) 24.11 (2.25–314.6) ns ns ns
VEGF ng/mL 0.33 (0.07–1.00) 0.32(0.09–0.95) 0.41 (0.15–1.41) ns ns ns
FST ng/mL 0.82 (0.27–3.79) 0.73 (0.28–2.41) 0.67 (0.23–4.33) ns ns ns
PAEP ng/mL 7.22 (1.03–51.82) 11.35 (4.92–38.84) 13.52 (0.70–79.68) ns ns ns
LUM ng/mL 47.05 (0.60–101.1) 41.7 (0.18–111,3) 45.0 (6.39–133.0) ns ns ns
TNC ng/mL 40.31 (11.27–152.2) 73.24 (13.47–154.7) 46.27 (7.09–182.4) ns 0.039 0.044
CPM ng/mL 3.83 (0.4–70.75) 4.32(0.02–38.03) 6.13 (0.4–94.62) ns ns ns
CRP mg/L 0.7 (0.6–9.2) 0.6 (0.6–10.0) 0.75 (0.6–20.0) ns ns ns
Candidate biomarker Secretory phase Proliferative phase




CA125 0.006 0.003 ns ns
oestrogen ns ns ns ns
progesterone ns ns ns ns
sICAM1 ns 0.026 ns ns
IL1R2 ns ns ns ns
MCP1 ns ns ns ns
MIF ns ns ns ns
VEGF 0.033 ns ns ns
FST ns ns 0.011 ns
PAEP ns ns ns ns
LUM ns ns ns ns
TNC ns 0.037 ns ns
CPM ns ns ns ns
CRP ns ns ns ns
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roles in this process. Lumican (LUM) has a role in cell 
migration and proliferation during embryonic develop-
ment, tissue repair and tumour growth through regula-
tion of matrix metalloprotease activity [15] and collagen 
fibrillogenesis [16]. In the endometrium, LUM expression 
was reported to increase in the secretory phase [17], in 
agreement with our findings. We also found multiple col-
lagens and other ECM glycoproteins and integrin ligands 
to be overexpressed in endometriotic samples, and 
particularly in ectopic versus eutopic tissue. One such 
protein, tenascin C (TNC), was reported to be regulated 
across the menstrual cycle and aberrantly in endometrio-
sis [18–20]. Our data suggest that its cyclic expression is 
lost in the endometrium of endometriosis patients, and 
whilst we did not observe TNC overexpression in ectopic 
lesions, its increased expression may promote adhesion 
and invasion of endometrial cells at ectopic sites.
Tropomyosins TPM1 and TPM2 play a role in mus-
cle contraction, motility, maintenance of cell shape and 
cell–matrix interactions through stabilisation of actin 
filaments. Expression of TPM2 was higher in ectopic 
versus eutopic tissue and increased in secretory phase 
eutopic tissue from endometriosis patients compared to 
both control groups. This may point to its involvement 
in mediating cellular structural changes that allow move-
ment and invasion of endometrial cells. The similarly 
expressed smooth muscle actin-binding protein TAGLN, 
may also be involved in this process and supports previ-
ous findings [21]. Increased expression of TPM1, TPM2 
and TAGLN may be the result of a higher smooth muscle 
content of deep endometriotic lesions. Another selected 
candidate was CPM; a GPI-anchored extracellular pepti-
dase that functions in processing of peptide hormones, 
chemokines and growth factors. It has a reported role in 
inflammation and stem cell mobilisation and has been 
shown to be up-regulated in endometrial epithelial cells 
during the proliferative phase [22]. The increased expres-
sion in endometriosis observed herein, may support the 
inflammatory response, although its lower expression in 
ectopic lesions is somewhat at odds with this.
Of particular note was the differential expression of 
the progesterone receptor (PGR). Several genes found 
to be dysregulated in the endometrium of endometriosis 
patients are known progesterone targets (Foxo1a, Mig6 
and Cyp26a1) and their overall pattern of expression 
suggested prolongation of the proliferative phase [23]. 
Indeed, incomplete transition of the endometrium from 
the proliferative to the secretory phase is a hallmark of 
endometriosis that has been attributed to progesterone 
resistance [24]. Our finding of reduced PGR expression 
in ectopic tissue has been previously reported as a possi-
ble mechanism of progesterone resistance [25]. However, 
whether the observed higher expression of PGR observed 
in eutopic endometrium from endometriosis patients is 
involved in progesterone resistance, or a response to it, 
is unclear. In part agreement with the literature [26–28], 
we also showed reduced expression of PGRMC1 and the 
progesterone target gene PAEP in endometriotic lesions; 
changes that may also contribute to progesterone resist-
ance in ectopic lesions.
CA125 was identified as the best single marker for dis-
criminating endometriosis from controls and featured 
Table 5 Performance of  cross-validated multi-marker 
models for  discriminating endometriosis from  control 
groups
Models were generated by logistic regression using up to 4 candidates with 
cross-validation by leave-one-out. The best performing models (by sensitivity) 
and area under the ROC curve (AUC) are reported for each comparison at fixed 
specificities of 0.90 or 0.80. E = endometriosis; C = no pain controls; P pain 
controls. Control groups were pooled (C + P) for some of the analyses
Models AUC Sensitivity Specificity
E versus C (all phases)
 CA125, sICAM1, CPM 0.768 0.667 0.8
 CA125, sICAM1, VEGF 0.777 0.644 0.8
 CA125, sICAM1, FST 0.77 0.644 0.8
 CA125, sICAM1 0.778 0.6 0.9
 CA125, sICAM1, IL1R2 0.758 0.6 0.9
 CA125, sICAM1, MCP1 0.757 0.6 0.9
E versus P (all phases)
 sICAM1, FST, TNC 0.679 0.667 0.8
 sICAM1, TNC 0.708 0.622 0.8
 sICAM1, TNC, Oestradiol 0.68 0.622 0.8
 sICAM1, PAEP, TNC 0.695 0.622 0.8
 sICAM1, MIF, PAEP 0.697 0.622 0.8
 sICAM1, LUM 0.665 0.444 0.9
E versus C + P (all phases)
 CA125, sICAM1, FST, CPM 0.706 0.578 0.8
 CA125, sICAM1, VEGF, PAEP 0.71 0.578 0.8
 CA125, sICAM1, PAEP 0.719 0.578 0.8
 CA125, sICAM1, MIF, PAEP 0.704 0.578 0.8
 CA125, MIF 0.621 0.467 0.9
E versus C + P (Proliferative)
 sICAM1, FST, Oestradiol 0.769 0.769 0.8
 sICAM1, MIF, FST 0.781 0.692 0.8
 sICAM1, FST 0.802 0.692 0.8
 CRP, sICAM1, FST 0.802 0.692 0.8
 CA125, sICAM1, FST 0.814 0.692 0.8
 sICAM1, MIF, FST 0.781 0.615 0.9
E versus C + P (Secretory)
 CA125, MIF, PAEP 0.705 0.654 0.8
 CA125, sICAM1, MIF 0.725 0.615 0.8
 CA125, MIF, TNC 0.683 0.615 0.8
 CA125, MIF, PAEP 0.705 0.538 0.9
 CA125, MIF, TNC 0.683 0.577 0.9
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prominently in the best-performing multimarker models. 
It is noteworthy that CA125 is currently the best single 
serum marker for ovarian cancer, although its median 
level in the endometriosis samples fell below the clinical 
threshold of 35 U/mL used for ovarian cancer detection. 
CA125 has been investigated extensively as a circulating 
marker of endometriosis, although lacks diagnostic accu-
racy when used alone. Our data supports this notion, 
with serum CA125 giving 40% sensitivity at 90% specific-
ity in our cohort. Its performance was also cycle-depend-
ent, being better at discriminating secretory phase 
samples. Cyclic differences in CA125 levels in endome-
triosis have been reported previously [29–32], although 
the diagnostic benefit of taking cycle stage into account 
is unclear. Soluble ICAM1 has also been investigated as 
a circulating marker with conflicting reports on its use-
fulness as a biomarker [33–37]. Our data do not support 
its use alone as a diagnostic marker, however its inclusion 
in our best classification models, suggests its value when 
combined with other markers, particularly CA125, FST 
and TNC.
Previous studies have tested panels of serum or plasma 
biomarkers, including those investigated here. Kocbek 
et  al. reported a model using the ratio of leptin to gly-
codelin/PAEP and age, with 83.6% sensitivity and 83.8% 
specificity for distinguishing ovarian endometriosis from 
controls independently of cycle phase [38]. Although also 
tested in this study, ICAM1, VEGF, CRP and MCP1 were 
not included in the reported best models, whilst CA125 
was not assessed. In another study, 28 plasma proteins 
were assessed in a large patient cohort, with an indepen-
dently validated model comprising CA125, annexin V, 
VEGF and sICAM1/or PAEP giving 81–90% sensitivity 
and 63–81% specificity for detecting endometriosis in the 
menstrual phase [39]. Other reported models including 
CA125, MCP1 and/or MIF showed reasonable diagnos-
tic accuracies [40, 41]. Whilst MCP1 added little to our 
models, MIF was in the best models for discriminating 
endometriosis from both control groups, particularly for 
the secretory phase. Our data thus corroborate CA125, 
sICAM1, PAEP, MIF and FST as potentially useful diag-
nostic markers when combined in multivariate models.
Conclusions
In conclusion, we have identified molecular changes 
associated with endometriosis in eutopic and ectopic 
tissue and have derived non-invasive, cycle phase-spe-
cific diagnostic models for endometriosis with respect-
able performance characteristics that are similar, if not 
better, than those reported previously. Our study has 
some weaknesses. Firstly, models were only tested by 
cross-validation on the same dataset with some evi-
dence of overfitting and subgrouping by cycle phase has 
underpowered the study. Thus, validation of these mod-
els in a larger independent cohort is necessary and should 
include samples from patients with other gynaecological 
conditions presenting with similar symptoms, particu-
larly gynaecological malignancies. This would allow bet-
ter assessment of the specificity of the biomarker panels. 
Secondly, our best biomarker model for discriminating 
endometriosis from the more relevant pain control group 
[sICAM1, FST, TNC] provided a sensitivity of 67% at 
80% specificity, and so its usefulness as a triage test for 
guiding surgery is debatable. However, taking cycle phase 
into account, one model provided 61.5% sensitivity at 
90% specificity, and so might be acceptable for triaging. 
Thirdly, whilst we show improved model performances 
by taking cycle-phase into account (particularly for pro-
liferative phase), this type of testing may be difficult to 
implement in clinical practice should the models be 
validated.
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